DBV Technologies SA ADR DBVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
-
DBV Technologies to Participate in Upcoming September Investor Conferences
-
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
-
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
-
DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies
Trading Information
- Previous Close Price
- $9.62
- Day Range
- $9.52–9.84
- 52-Week Range
- $8.63–26.19
- Bid/Ask
- $5.91 / $14.44
- Shares Outstanding
- 62.85M
- Market Cap
- $608.37M
- Volume/Avg
- 121,590 / 356,924
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 170
- Website
- https://www.dbv-technologies.com
Valuation
|
Metric
|
DBVT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DBVT
|
|---|---|
Quick Ratio | 3.54 |
Current Ratio | 3.72 |
Interest Coverage | — |
Quick Ratio
DBVT
Profitability
|
Metric
|
DBVT
|
|---|---|
Return on Assets (Normalized) | −82.43% |
Return on Equity (Normalized) | −119.10% |
Return on Invested Capital (Normalized) | −114.30% |
Return on Assets
DBVT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|fjb!>pG | LOCK|@md#y | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|w!%Y?Fc | LOCK|!F&BH | $84B | |||
| Moderna Inc
MRNA
| LOCK|ZMq$>&K | LOCK|T# | $81B | |||
| argenx SE ADR
ARGX
| LOCK|q@cmHF | LOCK|J%! | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|d#^^^r | LOCK|vj | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|yTtcMc | LOCK|tFd^! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|m>%W%@@ | LOCK|qXZJ | $28B | |||
| Incyte Corp
INCY
| LOCK|n!qX>p | LOCK|fF | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|yg@@!&! | LOCK|ChD | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!G@j<W# | LOCK|<xy | $14B |
United States